Isothermal titration calorimetry (ITC).

<p>For the ITC experiments, 2 mM peptide 19–2.5 was titrated to this dispersion stepwise in 3 μl portions into (A) 200 μg/ml heparan sulfate-fragments (HS) and (B) 100 μg/ml heparanase (Hep). In each titration, the resulting heat signals P were recorded (peak downwards are exothermic, peaks upwards endothermic reactions) against time (min) and presented in the top parts of Fig 5A and 5B. The integrated enthalpy changes ΔH versus [peptide]:[HS-fragments] (A) and [peptide]:[heparanase] (B) concentration ratios of the single titrations are illustrated in the bottom parts of Fig 5A and 5B.</p

Heparanase level in murine (A) and human (B) sepsis.

<p>Plasma was obtained from mice subjected to cecal ligature and puncture (CLP) and treated with peptide 19–2.5 (20 μg/ml, n = 6) or NaCl 0.9% as a control (n = 6). Moreover, plasma samples were collected from control healthy volunteers (n = 10) and from patients with septic shock (n = 18). Peptide 19–2.5 (20 μg/ml) was added ex vivo to the plasma. Data are presented as mean ± SD. P-values represent the statistical differences between groups using a multiple t-test with Holm-Šídák correction. ***p < 0.0001, n.s. = non significant.</p

Study population characteristics.

<p>APACHE II score (Acute Physiology and Chronic Health Evaluation II score), SOFA (Sequential organ failure assessment score)</p><p>Study population characteristics.</p

Relative mRNA expression of heparanase.

<p>Relative mRNA expression of heparanase were measured in lung (A), liver (B), spleen (C), heart (D) and kidney (E) of mice subjected to cecal ligature and puncture (CLP) and treated with peptide 19–2.5 (20 μg/ml, n = 6) or NaCl 0.9% as a control (n = 6). Data are presented as mean ± SD. P-values represent the statistical differences between groups using a multiple t-test with Holm-Šídák correction. **p < 0.01, ***p < 0.0001.</p

Heparanase activity in murine (A) and human (B) sepsis.

<p>Plasma was obtained from mice subjected to cecal ligature and puncture (CLP) and treated with peptide 19–2.5 (20 μg/ml, n = 6) or NaCl 0.9% as a control (n = 6). Furthermore, plasma samples were collected from control healthy volunteers (n = 10) and from patients with septic shock (n = 18). Peptide 19–2.5 (20 μg/ml) was added ex vivo to the plasma. Data are presented as mean ± SD. P-values represent the statistical differences between groups using a multiple t-test with Holm-Šídák correction. *p < 0.05, ***p < 0.0001, n.s. = non-significant.</p